Related Experiment Video

Updated: May 29, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Cardiovascular disease among hispanics and non-hispanics in the chronic renal insufficiency cohort (CRIC) study

Ana C Ricardo1, James P Lash, Michael J Fischer

  • 1Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

Clinical Journal of the American Society of Nephrology : CJASN
|September 8, 2011
PubMed

Insights

Cardiovascular disease (CVD) prevalence differs among Hispanic and non-Hispanic kidney disease patients. Hispanics showed higher left ventricular hypertrophy (LVH) and coronary artery calcification (CAC) risks, highlighting ethnic disparities in CKD complications.

Area of Science:

  • Nephrology
  • Cardiology
  • Epidemiology

Background:

  • Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD) patients.
  • Limited data exists on CVD prevalence specifically among the growing Hispanic population with CKD.

Purpose of the Study:

  • To investigate the prevalence of self-reported and subclinical CVD measures in Hispanic individuals with CKD.
  • To compare CVD prevalence across different racial and ethnic groups within the CKD population.

Main Methods:

  • Cross-sectional analysis of data from the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic CRIC (HCRIC) studies.
  • Inclusion of 497 Hispanics, 1638 non-Hispanic Caucasians, and 1650 non-Hispanic African Americans with mild-to-moderate CKD.
  • Assessment of subclinical CVD including left ventricular hypertrophy (LVH), coronary artery calcification (CAC), and ankle-brachial index.

Main Results:

  • Initially, Hispanics reported lower coronary heart disease (CHD) and lower prevalence of CAC >100 and CAC >400 compared to non-Hispanic Caucasians.
  • After adjusting for sociodemographic factors, these initial differences in CAC were not significant.
  • Adjusted analyses revealed a higher odds of LVH in Hispanics versus non-Hispanic Caucasians and higher odds of CAC >400 in Hispanics versus non-Hispanic African Americans.

Conclusions:

  • Prevalent left ventricular hypertrophy (LVH) is more common in Hispanic individuals with CKD compared to non-Hispanic Caucasians.
  • Elevated coronary artery calcification (CAC) scores are more prevalent in Hispanics compared to non-Hispanic African Americans.
  • Further research is needed to understand the reasons behind these racial/ethnic disparities in CVD and their impact on long-term outcomes in CKD patients.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...